RU2524152C2 - Средство для лечения ревматоидного артрита - Google Patents

Средство для лечения ревматоидного артрита Download PDF

Info

Publication number
RU2524152C2
RU2524152C2 RU2011142183/10A RU2011142183A RU2524152C2 RU 2524152 C2 RU2524152 C2 RU 2524152C2 RU 2011142183/10 A RU2011142183/10 A RU 2011142183/10A RU 2011142183 A RU2011142183 A RU 2011142183A RU 2524152 C2 RU2524152 C2 RU 2524152C2
Authority
RU
Russia
Prior art keywords
seq
amino acid
acid sequence
antibody
cdr1
Prior art date
Application number
RU2011142183/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2011142183A (ru
Inventor
Томоюки ИГАВА
Синя ИСИИ
Ацухико МАЕДА
Мика САКУРАИ
Тецуо КОДЗИМА
Тацухико ТАТИБАНА
Хиротаке СИРАИВА
Хироюки ЦУНОДА
Йосинобу ХИГУТИ
Original Assignee
Чугаи Сейяку Кабусики Кайся
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чугаи Сейяку Кабусики Кайся filed Critical Чугаи Сейяку Кабусики Кайся
Publication of RU2011142183A publication Critical patent/RU2011142183A/ru
Application granted granted Critical
Publication of RU2524152C2 publication Critical patent/RU2524152C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
RU2011142183/10A 2009-03-19 2010-03-19 Средство для лечения ревматоидного артрита RU2524152C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009-067358 2009-03-19
JP2009067358 2009-03-19
PCT/JP2010/054763 WO2010107108A1 (ja) 2009-03-19 2010-03-19 関節リウマチ治療剤

Publications (2)

Publication Number Publication Date
RU2011142183A RU2011142183A (ru) 2013-04-27
RU2524152C2 true RU2524152C2 (ru) 2014-07-27

Family

ID=42739764

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011142183/10A RU2524152C2 (ru) 2009-03-19 2010-03-19 Средство для лечения ревматоидного артрита

Country Status (5)

Country Link
JP (2) JP4809930B2 (enExample)
KR (1) KR101314880B1 (enExample)
RU (1) RU2524152C2 (enExample)
TW (1) TWI457134B (enExample)
WO (1) WO2010107108A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
MX2009007830A (es) 2007-01-23 2009-10-07 Univ Shinshu Inhibidor de rechazo cronico.
TW201503898A (zh) 2008-06-05 2015-02-01 Chugai Pharmaceutical Co Ltd 神經浸潤抑制劑
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
RS63800B1 (sr) 2010-05-28 2022-12-30 Chugai Pharmaceutical Co Ltd Poboljšanje antitumorskog odgovora t ćelije
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
EP3009518B1 (en) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Ｉｌ－６受體抗體用於製備醫藥組成物的用途
JP6875683B2 (ja) 2015-05-19 2021-05-26 国立研究開発法人国立精神・神経医療研究センター 多発性硬化症（ｍｓ）患者の新規治療適用判断方法
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
JPWO2020202839A1 (enExample) 2019-03-29 2020-10-08
AU2020259884A1 (en) 2019-04-17 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
US12558423B2 (en) 2020-05-29 2026-02-24 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation
CN117320749A (zh) 2021-03-12 2023-12-29 中外制药株式会社 用于治疗或预防重症肌无力的药物组合物
WO2025198912A1 (en) 2024-03-21 2025-09-25 Hoffmann-La Roche Inc. Methods of treating myasthenia gravis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2147442C1 (ru) * 1994-10-21 2000-04-20 Кисимото Тадамицу Фармацевтическая композиция для профилактики или лечения заболеваний, вызываемых образованием il-6

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2481356C2 (ru) * 2004-12-28 2013-05-10 Иннейт Фарма Моноклональные антитела против nkg2a
JP2010500876A (ja) * 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
WO2009010539A2 (en) * 2007-07-19 2009-01-22 Ablynx. N.V. Receptor for interleukin-6 (il-6) from macaca fascicularis
RU2505603C2 (ru) * 2007-09-26 2014-01-27 Чугаи Сейяку Кабусики Кайся Антитело против рецептора il-6
ES2687808T3 (es) * 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
TW201920257A (zh) * 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2147442C1 (ru) * 1994-10-21 2000-04-20 Кисимото Тадамицу Фармацевтическая композиция для профилактики или лечения заболеваний, вызываемых образованием il-6

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NISHIMOTO N. et al., "Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan." Clin Rev Allergy Immunol. (2005); 28(3):221-30. YOKOTA S. et al., Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis." Clin Rev Allergy Immunol. (2005); 28(3):231-8. *

Also Published As

Publication number Publication date
JP4809930B2 (ja) 2011-11-09
JP2011219478A (ja) 2011-11-04
TWI457134B (zh) 2014-10-21
JPWO2010107108A1 (ja) 2012-09-20
RU2011142183A (ru) 2013-04-27
KR101314880B1 (ko) 2013-10-04
KR20110139734A (ko) 2011-12-29
WO2010107108A1 (ja) 2010-09-23
TW201034685A (en) 2010-10-01

Similar Documents

Publication Publication Date Title
KR101314880B1 (ko) 관절류머티즘 치료제
KR101892883B1 (ko) Il-6 관련 질환 치료용 조성물
ES2932398T3 (es) Potenciador de la respuesta de las células T antitumorales
CA2648644C (en) Muscle regeneration promoter
KR101044180B1 (ko) 개량된 항체분자
RU2490025C2 (ru) Терапевтические средства, используемые против реакции трансплантат против хозяина, содержащие в качестве активного ингредиента ингибитор рецептора интерлейкина-6
US20240059750A1 (en) Dual cytokine fusion proteins comprising il-10
CA2717987C (en) Inhibitors of gm-csf and il-17 for therapy
JP2011173918A (ja) 改良された抗体分子を含有する製剤
TW200803895A (en) Method of using IL6 antagonists with proteasome inhibitors
KR20220109435A (ko) B형 간염 감염 치료에서의 사용을 위한 인터페론-결합된 항원 결합 단백질
AU2004209967A1 (en) Methods for modulating an inflammatory response
KR20170045222A (ko) 항-tnf-알파 항체 요법을 받은 건선 환자의 치료 방법
JP2005516907A (ja) 霊長類ｉｆｎ−ガンマ結合分子の使用
JP2010116338A (ja) 同一抗原に特異的に結合する複数の抗体の混合物もしくは複数の抗原結合部位を有する抗体
Gonzalez-Gonzalez et al. Secukinumab
HK1237650A1 (en) Composition for treating il-6-related diseases